BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

817 related articles for article (PubMed ID: 21159112)

  • 21. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis.
    Katz LH; Paul M; Guy DG; Tur-Kaspa R
    Transpl Infect Dis; 2010 Aug; 12(4):292-308. PubMed ID: 20002355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
    Patterson SJ; Angus PW
    Curr Opin Organ Transplant; 2009 Jun; 14(3):225-30. PubMed ID: 19373086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.
    Neff GW; Kemmer N; Kaiser TE; Zacharias VC; Alonzo M; Thomas M; Buell J
    Dig Dis Sci; 2007 Oct; 52(10):2497-500. PubMed ID: 17404847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation.
    Katz LH; Tur-Kaspa R; Guy DG; Paul M
    Cochrane Database Syst Rev; 2010 Jul; (7):CD006005. PubMed ID: 20614442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
    Saab S; Ham MY; Stone MA; Holt C; Tong M
    Liver Transpl; 2009 Apr; 15(4):413-20. PubMed ID: 19326401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
    Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
    Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review.
    Cholongitas E; Papatheodoridis GV
    Am J Transplant; 2013 Feb; 13(2):353-62. PubMed ID: 23137006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in prevention of hepatitis B recurrence after liver transplantation.
    Xi ZF; Xia Q
    World J Gastroenterol; 2015 Jan; 21(3):829-35. PubMed ID: 25624716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection.
    Perrakis A; Förtsch T; Del Medico A; Croner RS; Vassos N; Yedibela S; Lohmüller C; Zopf S; Hohenberger W; Müller V
    Transplant Proc; 2013 Jun; 45(5):1953-6. PubMed ID: 23769081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
    Yang Y; Zhang Q; Cai CJ; Lu MQ; Li X; Jiang N; Jiang H; Xu C; Li H; Wang GS; Yi SH; Zhang J; Zhang JF; Yi HM; Zhang YC; Chen GH
    Chin Med J (Engl); 2007 Aug; 120(16):1400-3. PubMed ID: 17825167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
    Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
    Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
    Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
    Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation.
    Hakim GD; Akarsu M; Karademir S; Unek T; Astarcıoğlu İ
    Turk J Gastroenterol; 2014 Dec; 25(6):685-9. PubMed ID: 25599782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.
    Cholongitas E; Goulis J; Akriviadis E; Papatheodoridis GV
    Liver Transpl; 2011 Oct; 17(10):1176-90. PubMed ID: 21656655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.
    Fung J; Chan SC; Cheung C; Yuen MF; Chok KS; Sharr W; Chan AC; Cheung TT; Seto WK; Fan ST; Lai CL; Lo CM
    Am J Gastroenterol; 2013 Jun; 108(6):942-8. PubMed ID: 23629601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues.
    Schreibman IR; Schiff ER
    Ann Clin Microbiol Antimicrob; 2006 Apr; 5():8. PubMed ID: 16600049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results.
    Taltavull TC; Chahri N; Verdura B; Gornals J; Lopez C; Casanova A; Cañas C; Figueras J; Casais LA
    Transpl Int; 2005 Jul; 18(7):879-83. PubMed ID: 15948869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
    Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
    J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.